Ascendia

  MARKET NEWS

Ocuphire Announces US Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
Aragen Operationalizes First Phase of its Biologics Manufacturing Facility in India
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion Into Autoimmune Diseases
Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report
Vidac Pharma Receives Japanese Patent Office Notice of Allowance for Cancer Drug Candidate

  FEATURED EDITORIAL

  COMPANY PROFILE

Pace® Life Sciences provides a full suite of contract CMC development, CTM manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Pace® Life Sciences operates from a network of CDMO sites, GMP analytical testing laboratories, and manufacturing support service centers across the United States. Our experienced, highly trained industry experts, and our investment in state-of-the-art development and manufacturing facilities emphasizes our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Teva & Abingworth Enter Strategic Development Funding Agreement

Teva & Abingworth Enter Strategic Development Funding Agreement

Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program….

Intravacc & Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Intravacc & Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

The companies will leverage their combined experience in the development of conjugate vaccines for their clients….

Abzena Announces Major Investment in Bioconjugation & ADC Capabilities in Response to Increasing Industry Demand

Abzena Announces Major Investment in Bioconjugation & ADC Capabilities in Response to Increasing Industry Demand

Abzena recently announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5-million investment in expanded laboratory….

Vector Pharma & Oncopeptides FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East & North Africa 

Vector Pharma & Oncopeptides FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East & North Africa 

Oncopeptides AB and Vector Pharma FZCO recently announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

WHITEPAPER - Manufacturing of 10-mg Loratadine Self-Emulsifying Drug Delivery System (SEDDS) Tablets by Direct Compression With ABISORB-DC & ABISOL Emulsion Preconcentrate Kit

Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

WHITEPAPER - Revolutionizing Small Molecule API Production: Unveiling the Impact of Fermentation as a Sustainable Solution

While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lines blurring between traditional chemical synthesis …

WHITEPAPER - Minimizing API Supply Chain Risks

WHITEPAPER - Minimizing API Supply Chain Risks

By the time your API is brought to a contract manufacturing organization (CMO), you have already put extensive amounts of resources into developing it. It becomes essential that you optimize your API supply chain to be aware of potential risks

…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 10 – Formulation Development
April 17 – Prefilled Syringes